Yuuki Miyauchi

Ehime University, Matuyama, Ehime, Japan

Are you Yuuki Miyauchi?

Claim your profile

Publications (5)6.69 Total impact

  • Pathology 07/2008; 40(4):431-4. · 2.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cisplatin-based combination chemotherapy has been considered as standard therapy for advanced or metastatic urothelial carcinoma. A recent study has, however, revealed that gemcitabine may have the potential to act synergistically with cisplatin. Therefore, the side effects of gemcitabine plus cisplatin (GC) therapy were compared with those of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) therapy in patients with advanced or metastatic urothelial carcinoma. Twenty-two patients received GC therapy. Gemcitabine (1000 mg/m2) was administered on days 1, 8 and 15 of each 28-day cycle. Cisplatin (70 mg/m2) was administered on day 2 of each cycle. As a control group, 24 patients received MVAC therapy (methotrexate at 30 mg/m2 on days 1, 15, 22, vinblastine at 3 mg/m2 on days 2, 15, 22, doxorubicin at 30 mg/m2 on day 2, and cisplatin at 70 mg/m2 on day 2 of each 28-day cycle. In the group of patients which received GC therapy, the overall response rates based on independent radiologic reviews of the 20 patients with measurable disease were 55%, with 20% CR and 35% PR. Fewer GC patients as compared with MVAC patients had grade 3/4 anorexia (4.5% vs. 75%, respectively), stomatitis (9.0% vs. 66.7%, respectively), and alopecia (27.3% vs. 100%, respectively). On the other hand, there were no significant differences in the incidence or pattern of hematologic toxicities between the group receiving GC therapy and that receiving MVAC therapy. Fatal neutropenic sepsis occurred in one patient receiving MVAC therapy. GC therapy is effective for the treatment of advanced or metastatic urothelial carcinoma, with an acceptable clinical safety profile. This study also indicates that GC therapy may be better tolerated and safer than MVAC therapy.
    Nippon Hinyōkika Gakkai zasshi. The japanese journal of urology 10/2006; 97(6):777-81.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In a 32-year-old pregnant woman, routine ultrasonography revealed right hydronephrosis and a huge retroperitoneal mass (20 x 7 cm) containing a fluid collection. Percutaneous drainage of the mass was performed and 2 L of clear, yellowish fluid was collected. Four months following the delivery, a recurrent retroperitoneal lymphocele was identified. Six months after the delivery, laparoscopic marsupialization was performed through a 10-mm umbilical camera port and two 5-mm ports on the right side of the abdomen. A posterior peritoneal window was established by creating a wide opening in the anterior wall of the lymphocele. Subsequent ultrasonography did not indicate a recurrence of the lymphocele or right hydronephrosis over a follow-up period of 8 months.
    International Journal of Urology 05/2006; 13(4):445-6. · 1.73 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Therapeutic approaches directed at reducing proteinuria are under development. The aim of the present study was to prospectively elucidate the impact of losartan treatment in renal transplant recipients with persistent proteinuria. Twenty-eight patients with persistent proteinuria or mild hypertension were assigned to receive losartan. Proteinuria was defined as a ratio of urinary protein to urinary creatinine (U(P)/U(Cr)) >0.5 in continual urinary tests in the outpatient setting. All patients with mild hypertension reached target blood pressure (BP) with losartan treatment, but the change was not significant. In twelve patients with proteinuria before initiation of the study, urinary protein excretion was significantly reduced with treatment. No correlation was observed between reductions in proteinuria and mean BP. A significant decrease was identified in the hemoglobin concentration of patients with serum creatinine concentrations >2.0 mg/dl before the study. Losartan efficiently reduces proteinuria in renal transplant recipients with adequate tolerance. Multicentric prospective studies are required to confirm its clinical effectiveness.
    In vivo (Athens, Greece) 01/2004; 18(4):433-6. · 1.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Urinary tract infection is a complication of hydronephrosis and antibiotics such as gentamicin are indicated for treatment. However, gentamicin can cause drug-induced nephropathy in dehydrated patients. We used a rat kidney model to investigate the effects of gentamicin administration on functional recovery from unilateral hydronephrosis. Gentamicin was intraperitoneally injected twice for 48 hours following the release of a unilateral ureteral obstruction. The function of both kidneys was separately quantified by Technetium-99mDMSA renoscintigraphy. We examined morphological changes in renal tubular cells by electron microscopy and by in situ DNA 3'-end labeling. Renal function in the contralateral, but not the obstructed, kidney was significantly damaged by gentamicin administration under our conditions and electron microscopy confirmed the presence of myeloid bodies in renal tubular cells. In situ DNA 3'-end labeling revealed characteristic damage to the renal tubules. These results suggest that damage to each kidney should be considered individually after gentamicin administration during recovery from hydronephrosis.
    In vivo (Athens, Greece) 17(2):125-8. · 1.15 Impact Factor